Nestle Health Science

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
—Microbiome therapeutic
Clostridioides Difficile Infection
Recurrent Clostridioides Difficile Infection

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$8.0B———report ↗